RNL BIO CO., LTD. (KOSPI CODE : ) Investor Relations 2007

Transcription

1 RNL BIO CO., LTD. (KOSPI CODE : ) Investor Relations 2007 Jeong Chan Ra President and CEO

2 Safe Harbor This presentation may contain forward looking statements including projections and business trends. Actual results may differ materially from the anticipated results and expectations expressed in these forwardlooking statements as a result of certain risks and uncertainties. These forward-looking statements are made based upon information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.

3 Investor Relations Contents Company Profile World s Leading Korean Stem Cell Industry Industry Leading RNLBIO Company Value Vision

4 Company Profile World s Leading Korea Industry- Leading RNLBIO Company Value Vision Company Profile

5 Introduction of RNL BIO Company Profile Company Industry division Headquarter RNL BIO CO.,LTD CEO Life science product, Food, Biomedicine Market Capital Bongcheon-Dong, Kwanak-Gu, Seoul, Korea Jeong Chan Ra $ million (as of Sep ) 2010 World best stem cell company 2003 Providing stem cell therapy to over 100 countries Jan Oct Snucop got a patent (Achieved KT mark) Best prize for venture company Stem cell therapy approval Clinical trial on stem cell therapy Aug Jul Nov Approved as a Promising Small business administration Approved as the best venture company 2001 Selected as a government project (Ministry of commerce, Industry & Energy) International collaboration network with USA/Europe World largest stem cell GMP facility Participated in Therapeutic application of Cord Blood derived stem cell Program Went public via stock swap with Daewon ENT (KOSPI, Seou, Korea) Nov Incorporated Aug Jul Approved Veterinary medicine Manufacturing Research Institute established

6 Management team Executives Name Title Career Chang Yeul Lim Chairman Deputy Prime Minister and Finance Minister, Kyunggi Province Governor Jeong Chan Ra President and CEO Professional group of Ohsong international bio expo Seoul national university veterinary college (DVM) LG chemistry, Bayer Korea team leader Yong Ho Park Inspector Dean of Seoul national university veterinary college professor Director of Korea food and drug administration Washington state university, Idaho university plural professor Young Soon Lee Director Dean of Seoul national university veterinary college- prior Seoul national university veterinary college professor Sae Hyun Bak Director Professor of Korea Univ college of medicine Korea Kuro hospital (Head of endocrine internal medicine) Kyung-sun Kang Director Seoul national university veterinary college professor Byung Gi Kim Director Seoul national university (Professor of veterinary college) Bayer Korea- animal medicine (Chief of research) Dae han new pharm executive director

7 Advisory Board Dr. Lester M. Crawford Dr. Keith L. March Dr. Kyung-Sun Kang FDA commissioner 2004former director of US FDA Chair of the Department of Physiology- Pharmacology at the University of Georgia Director of the Center for Food and Nutrition Policy at Georgetown University and at Virginia Tech Doctor of Veterinary Medicine (DVM) from Auburn University PhD in pharmacology from the University of Georgia Professor at Indiana University Professor of Biomedical Engineering/ Cellular and Integrative Physiology/ Medicine Director, Indiana Center for Vascular Biology and Medicine President of International Fat Applied Technology Society Ph.D., Biochemistry, Indiana University M.D. Indiana University School of Medicine Professor at Seoul National University Board director at RNL Bio, Co Ltd. Advisory council at Korea Food and Drug Administration Visiting professor at U of British Columbia Assistant professor at Michigan State University BS, MS, PhD from Seoul National University

8 Mission Statement RNL BIO CO.,LTD is a pharmaceutical company dedicated to development and commercialization of stem cell based therapeutics for the treatment of degenerative and obstinate human diseases.

9 Company Profile World s Leading Korea Industry- Leading RNLBIO Company Value Vision World s Leading Korea

10 Hwang s s Scandal hope and hype

11 Competence of Korean stem cell industry 출처 줄기세포 기술 경쟁력 현황 및 대응전략 2006년 12월

12 World s s Leading Korean Biotech Industry

13 Company Profile World s Leading Korea Industry- Leading RNLBIO Company Value Vision Industry- Leading RNLBIO

14 RNL Bio is a industry-leading stem cell biotech company Success in Stem Cell Therapeutics Stable financials 1 Focused development 2 3 Proprietary Technology Commercialization Readiness Strong Pipeline Well developed stem cell technology Superior efficacy and safety profile Area s Largest GMP Facility Global Network Under Clinical Development Clinical development of nine indications at the same time

15 Proprietary Technology Patented propriety adult stem cell isolation technology from various tissues Stem Cells form Fat, Placenta, Cord Blood, Hair Follicles Expansion technology Patent portfolio Patent issued : 16 Patent pending : 25 Licensed : 5

16 Commercialization Readiness Facility State of the arts stem cell GMP facility was built in 2006 Global network with world s renowned institutes Plan to get the first Korean stem cell product clinically tested in the US Investigational New Drug application was filed in Korea

17 GMP Facility One of World Largest Stem Cell facilities

18 Global Network

19 Strong product pipeline Largest number of indications to be clinically tested IND application within 6 months Limb Ischemia, Heart Infarction, Breast Reconstruction, Urinary Incontinence, Spinal Cord Injury, Avascular Necrosis, Alopecia Both autologous and allogeneic application available Autologus application free of immune rejection Allogeneic application to avoid aged source or genetic background

20 Limb Ischemia Buerger s disease, diabetic foot ulcer 2.5 billion dollars market Competitor: Osiris(Phase II) Aldagen(Phase I) Initiation Phase I (1H 2008) 10 million patients with ischemic disease 100,000 amputation per year Buerger s disease

21 Myocardial Infarction Market size: 33 billion dollars in the US Competitor: Baxter, Aastrom, ViaCell, Cytori, Geron, Osiris 4.9 million patients with heart failure 700,000 annual incidence Leading cause of death less than 40% 5yr survival rate Eligible for orphan drug designation Heart attack Stem Cell Treatment Damaged heart muscles Restored Function

22 Spinal Cord Injury US Market Size: 16.5 billion dollars 254,000 patients in US 11,000 annual incidence Competitors: Geron, Aastrom Lifetime caring individual patient costs 400,000 to 2.7 million Before After

23 Alopecia: Hair loss US Market Size: 10 billion dollars Stem cells from Hair follicle isolated and tested for efficacy Before After

24 Clinical Development Program IN KOREA Limb Ischemia Myocardial Infarction Osteoarthriti s Preclinical Phase I Phase II Phase III Marketed Spinal Cord Injury

25 IN USA Clinical Development Program Limb Ischemia Myocardial Infarction Osteoarthriti s Preclinical Phase I Phase II Phase III Marketed Spinal Cord Injury

26 Company Profile World s Leading Korea Industry- Leading RNLBIO Company Value Vision Company Value

27 Rights offering US credit agony

28 P/L Financials (Unit : Mil.KRW) FY2007(2/4) FY2007(E) FY2008(E) FY2009(E) Sales 4,871 15,031 24,360 31,180 Gross Profit ,991 15,522 19,927 (%) (-10.9) (33.2) (63.7) (63.9) SG&A 4,821 9,639 13,902 15,292 (%) (98.9) (64.1) (57.0) (49.0) Operationg Income -5,352-4,648 1,620 4,635 (%) (-109.8) (30.9) (6.7) (14.9) Net Income BeforeTax -6,083-5, ,021 (%) (-124.8) (36.8) (2.8) (12.9) Net Income -6,083-5, ,021

29 B/S Financials (Unit : Ml.KRW) FY 2007 FY 2008(E) FY 2009(E) ASSET 43,503 53,183 67,267 LIABILITIES 8,675 9,514 11,301 (DEBT) 6,000 5,500 5,000 Shareholders Equity 34,828 43,669 55,966 Debi to Equity Ratio 25% 22% 20% Equity Ratio 80% 82% 83% R O E (-19%) 2% 8% 시가총액 121, , ,065

30 Right time for investment? Stock has been approaching bottom price Financing was under progress now finished Cash burn during intensive development technology development is finished Value adding clinical milestones are coming Milestone based re-valuation Cash cow business launched Stem cell banking, licensing out, stem cell cosmetics

31 Clinical Development Stages Limb Ischemia Preclinical Phase I Phase II Phase III Marketed Myocardial Infarction Osteoarthritis Spinal Cord Injury

32 Competitors in clinical stage Marketed Phase III Phase II Phase I RNL 2009 Osiris Aastrom ViaCell Cytori StemCells RNL Preclinical R&D ISC Geron ACT M$ Market Capitals

33 Cash Cow Business Stem Cell Banking Cord Blood Stem Cells Placenta Stem Cells Adipose Stem Cells Hair Stem Cells Stem Cell Cosmetics RPC Therapy for Facial Wrinkle Hair Stem Cell Injection for Alopecia Stem Cell Technology licensing Stem Cell Therapy Stem Cell Distribution Related Reagents Stem Cell Banking Stem Cell Cosmetics Stem Cell Research Product

34 Stem Cell Cosmetics: RPC therapy Annual Worldwide Botox Sales is more than $10B Stem cell as facial filler, displacing Botox Regenerating blood vessels and collagen fibers More effective, safer and longer lasting Line Epiderm Wrinkle Endoderm Adipose tissue Fold Adipose derived Stem Cell Blood vessel regen Collagen regen

35

36 Facial Application Cheeks Naso-Labial Eyelids Lips Chin Forehead

37 Clinical result 1 Clinical example (4 1/2 month after treatment) Male patient, 54 years old (2007) Before After

38 Clinical result 2 Diminishing facial dents Female patient 26 yrs old Before After

39 Clinical result 3 Female patient (51 years old) Treatment at temples on her head Before After

40 Is it the right time to invest? YES! One to three years later, RNL stem cell therapeutics is expected to be successfully commercialized and cash cow business to be on track In that period, a few orders of magnitude increase in market capital is possible along with clinical development and the performance of cash cow business.

41 Company Profile World s Leading Korea Industry- Leading RNLBIO Company Value Vision Vision

42 VISION RNL BIO as a world s best biotech company with global business network to more than one hundred countries including USA and EU through, Vision, Open Mind and Appreciation.